
    
      This is a Phase Ib/IIa prospective, multicenter, double blind, randomized, placebo
      controlled, clinical study to evaluate the safety, tolerability and pilot therapeutic
      activity of ORE1001, administered as capsules by mouth, for 6 weeks in subjects with
      Ulcerative Colitis.

      Eligible subjects will be randomly assigned to either ORE1001 or placebo, respectively.
      Sigmoidoscopies with biopsies will be performed at the first treatment visit and week 6.

      Subjects will be instructed to self-administer the study drug on an outpatient basis and will
      be scheduled to return for clinical evaluation on weeks 2, 4, 6 and between Weeks 10-12.
    
  